Juvenile myoclonic epilepsy - PowerPoint PPT Presentation

1 / 93
About This Presentation
Title:

Juvenile myoclonic epilepsy

Description:

... used alone, and again increase the dose until seizure control occurs or toxicity ... anticonvulsant drugs is different in the young, the elderly, pregnant women, ... – PowerPoint PPT presentation

Number of Views:762
Avg rating:3.0/5.0
Slides: 94
Provided by: Comp837
Category:

less

Transcript and Presenter's Notes

Title: Juvenile myoclonic epilepsy


1
(No Transcript)
2
Epilepsyfor the students
  • Amir M. Arain, M.D.
  • Vanderbilt University

3
Definitions
  • Epileptic seizure
  • The clinical manifestations(symptoms and signs)
    of excessive and hypersynchronous, usually self
    limited, activity of neurons in the cerebral
    cortex.
  • Epilepsy
  • A chronic disorder characterized by recurrent
    (more than 2) unprovoked seizures.

4
The ILAE classification of seizures
  • I. Partial (focal, local) seizures
  • A. Simple partial seizures(consciousness not
    impaired)
  • B. Complex partial seizures (with impairment of
    consciousness)
  • C.partial seizures evolving to generalized
    seizures

5
Simple partial seizure
6
Simple Partial seizure
7
Complex Partial seizureTemporal lobe
8
Partial secondarily generalized
9
The ILAE classification of epileptic seizures
  • II. Generalized seizures
  • A. Absence seizures
  • 1. Absence seizures
  • 2. Atypical absence seizures
  • B. Myoclonic seizures
  • C. Clonic seizures
  • D. Tonic seizures
  • E. Tonic-clonic seizures
  • F. Atonic seizures (astatic seizures)
  • III. Unclassified seizures

10
Myoclonic seizure generalizing
11
Absence seizure
12
Absence seizure complex
13
Atonic seizure
14
The International League Against Epilepsy
classification of epilepsies and epileptic
syndromes
  • I. Localization-related (focal, local, partial)
    epilepsies and syndromes
  • A. Idiopathic (with age-related onset). At
    present, two syndromes are established1. Benign
    childhood epilepsy with centrotemporal spike
  • 2. Childhood epilepsy with occipital paroxysms
  • B. Symptomatic. This category comprises syndromes
    of great individual variability.

15
The International League Against Epilepsy
classification of epilepsies and epileptic
syndromes
  • II. Generalized epilepsies and syndromes
  • A. Idiopathic (with age-related onset, in order
    of age appearance) 1. Benign neonatal familial
    convulsions 2. Benign neonatal convulsions 3.
    Benign myoclonic epilepsy in infancy 4.
    Childhood absence epilepsy (pyknolepsy, petit
    mal) 5. Juvenile absence epilepsy 6. Juvenile
    myoclonic epilepsy (impulsive petit mal) 7.
    Epilepsy with grand mal seizures on awakeningB.
    Idiopathic, symptomatic, or both (in order of age
    of appearance) 1. West's syndrome (infantile
    spasms)
  • 2. Lennox-Gastaut syndrome 3.
    Epilepsy with myoclonic-astatic seizures 4.
    Epilepsy with myoclonic absences

16
The International League Against Epilepsy
classification of epilepsies and epileptic
syndromes
  • C. Symptomatic1. Nonspecific cause. Early
    myoclonic encephalopathy2. Specific syndromes.
    Epileptic seizures may complicate many disease
    states. Under this heading are included those
    diseases in which seizures are a presenting or
    predominant feature.
  • III. Epilepsies and syndromes undetermined as to
    whether they are focal or generalizedA. With
    both generalized and focal seizures 1.Neonatal
    seizures 2. Severe myoclonic epilepsy in
    infancy 3. Epilepsy with continuous spikes and
    waves during slow-wave sleep 4. Acquired
    epileptic aphasia (Landau-Kleffner syndrome)
  • B. Without unequivocal generalized or focal
    features

17
Frontal Lobe seizure Orbitofrontal
18
Frontal lobe seizure
19
Pseudoseizure
20
The International League Against Epilepsy
classification of epilepsies and epileptic
syndromes
  • IV. Special syndromesA. Situation-related
    seizures 1. Febrile convulsions 2. Seizures
    related to other identifiable situations, such as
    stress, hormones, drugs, alcohol, or sleep
    deprivationB. Isolated, apparently unprovoked
    epileptic eventsC. Epilepsies characterized by
    the specific modes of seizures precipitatedD.
    Chronic progressive epilepsia partialis continua
    of childhood

21
Seizure precipitants
  • Stress, emotion
  • Sleep/sleep deprivation
  • Hyperventilation
  • Fever
  • Medications, metabolic disturbance
  • Reflex epilepsy
  • Photic stimuli TV, flashing lights, visual
    patterns
  • Startle, music, reading, eating

22
Case
  • 18yr female admitted in the Epilepsy lab for
    evaluation of recurrent spells.These atypical
    spells are associated with lightheadedness.
    Without warning he would become unresponsive and
    go limp. Myoclonic jerks were noted in the
    upper extremities. The pt. typically did not have
    vocalization, urinary or fecal incontinence or
    tongue biting

23
Case
  • Neurologic exam ---- normal
  • EEG ---- normal
  • MRI ---- normal
  • EKG episodes of asystole were recorded with
    patients typical spell
  • Patient became asymptomatic after implantation of
    a cardiac pacemaker.

24
All that jerks is not a seizure
  • Syncope
  • Hyperventilation/panic attacks
  • Migraine and migraine equivalents
  • Paroxysmal movement disorders.
  • Sleep disorders
  • TIAs
  • TGA

25
Syncope
26
Syncope
27
  • Non epileptic seizures
  • PPt by stress
  • Quivering, side-to-side movements of the head,
    pelvic thrusting, and uncontrolled flailing,
    thrashing, or asynch. rhythmic mov.of the limbs
  • Variable features
  • Eyes closed
  • No post-ictal change
  • Refractory to adequate AED levels
  • Prolonged duration
  • Normal prolactin
  • Rare but do occur
  • Epileptic seizures
  • Can be ppt by stress
  • Stereotypical
  • Constant features
  • Usually eyes open
  • Post ictal state
  • Responsive to AEDs
  • Seconds to minutes
  • Elevated prolactin
  • Self-injury and incontinence of urine or stool

28
Pseudoseizure
29
Generalized Absence (GA) vs Complex partial (CP)
sezures
30
Case
  • 22y male developed seizure disorder at 15yrs of
    age. Prior neurologic exam was unremarkable. Over
    the years patient has experienced GTC shortly
    after awakening, often precipitated by sleep
    deprivation and excess alcohol use. In the early
    morning hours after awaking body jerks would
    appear, interfering with eating and dressing

31
Juvenile myoclonic epilepsy
  • This is a common idiopathic generalized epileptic
    syndrome that occurs in 5 to 10 of patients
    with epilepsy.
  • A study in the United Kingdom demonstrated a mean
    interval of 14.5 years between onset of symptoms
    and diagnosis of JME.
  • Characterized by myoclonic seizures GCTC
    seizures in about 90 of patients, and absence
    seizures ( 30 ).
  • Seizure precipitants Emotional stress, alcohol,
    and recreational drug use can also increase
    seizure frequency in JME, and, to a lesser
    extent, flickering lights and menstruation.
  • Sleep deprivation is another common seizure
    precipitant. late nights of studying or parties
    frequently result in morning myoclonic seizures
    or GTCS.

32
(No Transcript)
33
JME Management
  • Lifestyle modification avoidance of sleep
    deprivation, alcohol.
  • For the majority of patients, JME is usually a
    lifelong condition and cessation of medication
    leads to relapse in 80-90 of patients.
  • The drug of choice is sodium valproate.
  • Clonazepam is an effective alternative, but its
    cognitive side effects, especially with long term
    use, make it less accepted by patients.
  • Lamotrigine is effective, both as add-on therapy
    and monotherapy, especialy if VPA side effects of
    weight gain, tremor and hair loss can not be
    tolerated

34
Workup of a first unexplained seizure.
  • High resolution MRI
  • EEG
  • 1 Unexplained seizure does not necessitate AED
    treatment except
  • Recognized epileptic syndrome with high
    probability of recurrence.
  • Focal brain lesion.

35
(No Transcript)
36
Treat or not to Treat
  • The risk of recurrence of seizures is about
    30-35 after the first unprovoked seizure
  • The risk of recurrence is about 70 after second
    seizure

37
EEG yield
  • 1st EEG 50
  • With repeated EEG and activation procedures the
    yield can go up to 90
  • No benefit after the fourth EEG, as it gives
    maximum yield

38
(No Transcript)
39
(No Transcript)
40
(No Transcript)
41
(No Transcript)
42
(No Transcript)
43
Drug Therapy basic principles
  • Use a single drug whenever possible.
  • Start low and go slow
  • Increase the dose of that drug to either seizure
    control or toxicity (decreasing the dose if
    toxicity occurs).
  • If a drug does not control seizures without
    toxicity, switch to another appropriate drug used
    alone, and again increase the dose until seizure
    control occurs or toxicity intervenes.

44
Drug Therapy basic principles
  • Remember that the "therapeutic range" is a
    guideline and not an absolute. Some patients
    achieve seizure control with blood concentrations
    below the range, and others tolerate
    concentrations above the range without toxicity.
  • Consider using two drugs only when monotherapy is
    unsuccessful. Keep in mind that some patients may
    have more seizures when taking two drugs rather
    than one drug because of drug interactions.

45
Drug Therapy basic principles
  • Be aware that the ability to metabolize
    anticonvulsant drugs is different in the young,
    the elderly, pregnant women, and people with
    certain chronic diseases, especially hepatic and
    renal disease, than in healthy, nonpregnant
    adults.

46
Pharmacokinetic overview of classical AEDs
PHT
CBZ
VPA
PHB
PMD
ESX
CZP
Bioavailability
gt90
75-85
gt90
gt90
gt90
gt90
gt80
Protein binding
90
75
90
45
lt20
lt10
86
Metabolism
95
gt95
gt96
lt80
Metabolism site
Liver
Liver
Liver
Liver
Liver
Liver
Liver
7-42
6-20
5-15
65-110
8-15
30-60
30-40
T1/2
no
yes
no
no
no
no
no
Autoinduction
47
Classical AEDs idiosynchriatic toxicity
Rash, lymphadenopathy
PHT
Rash, other hypersensitivity
CBZ
Liver failure, pancreatitis (rare)
VPA
PHB
Rash, connective tissue disorders
Connective tissue disorders
PMD
Blood dyscrasias
ESX
-
CZP
48
Pharmacokinetic overview of newer AEDs
FBM
GPN
LTG
TOP
TGB
LEV
OXC
ZNS
Absorption dose dependent bioavailability Tmax
(hrs)
no
yes
no
no
no
no
no
no
gt90
60
gt98
gt80
gt89
100
99
100
1-4
2-3
1.4-4.8
1-4
0.9-2.6
1
4-6
2-6
Protein binding
25
0
55
15
96
0
40
40
18-24
5-8
12-70
20-30
2-9
6-8
9
63
T1/2
no
no
slight
no
no
no
no
no
Autoinduction
applies to monohydroxyderivative (MHD), the
main active metabolite
49
Pharmacokinetic overview of newer AEDs - continued
FBM
GPN
LTG
TOP
TGB
OXC
ZNS
LEV
Metabolized?
50
no
90
20-50
98
99
65
40
Metabolism site
hepatic
NA
hepatic
hepatic
hepatic
liver
liver
blood
Elimination
urine
urine
urine
urine
feces (2/3)
urine
urine
urine
urine (1/4)
50
Effect of newer AEDs on blood concentration of
established AEDs
AED serum concentration with add-on
FBM GPN LTG TPM TIA LEV OXC ZNS
CBZ

PHT
VPA
an increase in PHT level may occur at high OXC
doses
51
Effect of established AEDs on blood concentration
of newer AEDs
AED serum concentration with add-on
CBZ PHT VPA
FBM
GPN
LTG
TPM
TGB
LEV
OXC
ZNS
52
New AEDs most concerning toxicity
Aplastic anemia, liver failure
FBM
-
GPN
Skin rash
LTG
TPM
Agitation, psychosis, speech disorder
Encephalopathy, psychosis
TGB
LEV
-
Rash, hyponatremia
OXC
Agitation, psychosis
ZNS
53
Case
  • A 27 yr women with history of epilepsy has just
    received her positive pregnancy test. She is on
    Carbamazepine. Her seizure frequency is 1-2
    seizures in six months.
  • She in concerned about teratogenic effects of the
    medication.
  • Should we take her off the medication?

54
GUIDELINES FOR THE MANAGEMENT OF EPILEPSY DURING
PREGNANCY
  • Baseline antiepileptic drug (AED) levels
    (total/free) and folate (serum/RBC)
  • Folate supplementation level 1-4 mg/day
  • Maternal alpha-fetoprotein level at week 15-16
  • AED levels and fetal ultrasound at 18-19 weeks
  • Repeat fetal ultrasound at 22-24 weeks
  • AED levels at 34-36 weeks. Make adjustments to
    ensure therapeutic drug levels at term.
  • Vitamin K 20 mg/day during eighth month or 10
    mg IV 4 hours before birth
  • and 1 mg IM to newborn at birth
  • Monthly AED levels postpartum for 12 weeks

55
Drug therapy
  • Partial and Secondarily
  • Generalized Seizures
  • Carbamazepine, phenytoin, and valproic acid are
    the first-line agents among most specialists for
    partial and secondarily generalized seizures
  • Gabapentin, lamotrigine, oxcarbazepine,
    tiagabine, topiramate, and vigabatrin are new
    anticonvulsants that are recommended for
    treatment of partial seizures.

56
Generalized seizures
  • Primary Generalized Seizures
  • Ethosuximide and valproic acid are equally
    effective for treating absence seizures, but
    ethosuximide is not effective for treatment of
    primary generalized tonic-clonic seizures.
  • Other AEDs
  • lamotrigine topiramate
  • felbamate tiagabine
  • zonisumide

57
Case
  • 30yr male with history of epilepsy has been
    seizure free on valproate for the last 2.5 years.
    He is not having any side effects. He is
    wondering if we can take him off medication.
  • What should we do?

58
Discontinuing AEDs
  • Seizure free 2-5 years on AEDs
  • Single type of partial or generalized seizures
  • Normal neurologic examination and normal IQ
  • EEG normalized with treatment
  • Relapse 31.2 children, 39.4 adults

59
(No Transcript)
60
What is status epilepticus?
  • Epileptic seizure that is prolonged or so
    frequently repeated as to create a fixed and
    lasting epileptic condition.
  • 30 min.

61
(No Transcript)
62
The Treatment of Generalized Convulsive Status
Epilepticus
  • Amir M. Arain, M.D.
  • Department of Neurology
  • Vanderbilt University Medical Center

63
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Goals
  • Treatment initiated immediately on arrival
  • Neuro resident evaluates patient ASAP
  • Seizures to be controlled ASAP
  • Plan transfer to NCU/ MICU
  • If seizures not controlled in 10-15 minutes,
    advance to phase II per physicians judgement

64
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Treatments
  • IV access
  • Pulse Oximetery
  • Cardiac monitor

65
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Labs
  • Blood glucose at bedside
  • SMA 6, SMA 12
  • CBC with diff and platelets
  • If on AEDs check AED levels
  • Hold urine and serum specimen

66
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Tests
  • CXR if indicated when status controlled
  • EKG if indicated when status controlled
  • Schedule CT without contrast if status not
    explained by
  • AED withdrawal
  • Metabolic or toxic disorder
  • CT can be done when status is controlled prior to
    transfer to NCU

67
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Meds/IV
  • IV- NS at KVO
  • If blood glucose low 1 amp D50 (50 cc IVP) and
    start second IV with D5NS
  • Thiamine 100 mg IVP if
  • given D50
  • cachectic/ malnourished
  • alcoholic

68
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Meds/IV
  • If actively seizing
  • 1) Diazepam IV, max 20 mg at lt 5 mg/min
  • or
  • Lorazepam IV, max 10 mg at lt 2mg/min

69
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Meds/IV
  • 2) Fosphenytoin (Cerebryx)- max delivery
    rate150mg/min, total dose 20 mg/Kg (marketed in
    phenytoin equivalent)
  • Do not use if status is due to a metabolic cause
    unlikely to respond to phenytoin
  • Reduce delivery rate if AV block or hypotension
  • Current treatment with phenytoin is not a
    contraindication

70
VUMC Status Epilepticus Pathways-Phase I 0-15
min (ED)- Meds/IV
  • Magnesium sulfate may be used if appropriate
  • If not actively seizing, fosphenytoin may be
    given without a benzodiazepine

71
VUMC Status Epilepticus PathwaysPhase II 15-60
min (ED-NCU) Goals
  • For continued uncontrolled seizures
  • Intubate and ventilate patient
  • Control seizures ASAP
  • Complete EEG
  • For patient with decreasing seizures
  • Additional dose of fosphenytoin
  • Transfer to NCU or MICU when stable

72
VUMC Status Epilepticus PathwaysPhase II 15-60
min (ED-NCU) Treatments
  • Continuing
  • IV access
  • pulse oximetery
  • New
  • Foley catheter
  • Intubate for uncontrolled seizures
  • Ventilate

73
VUMC Status Epilepticus PathwaysPhase II 15-60
min (ED-NCU) Labs
  • Phenytoin level 30 minutes after loading dose
    completed

74
VUMC Status Epilepticus PathwaysPhase II 15-60
min (ED-NCU) Tests
  • CT (without contrast) when seizures controlled
  • EEG (not necessary if patient wakes up). Contact
    EEG tech at time of ED admission
  • LP if indicated

75
VUMC Status Epilepticus PathwaysPhase II 15-60
min (ED-NCU) Meds/IV
  • For patients with decreasing seizures after
    fosphenytoin load additional 10 mg/Kg of
    fosphenytoin
  • For patients continuing to seize, who require
    intubation
  • Thiopental succinylcholine (avoid if possible)
  • Consider additional dose of fosphenytoin 10mg/Kg,
    or phenobarbital/pentobarbital

76
VUMC Status Epilepticus PathwaysPhase II 15-60
min (ED-NCU) Meds/IV
  • For continuing seizures post-intubation
    phenobarbital load or pentobarbital coma
  • phenobarbital 20 mg/Kg at lt 100 mg/min
  • if hypotensive, decrease rate of delivery
  • pentobarbital 5 mg/Kg loading dose (to achieve
    burst suppression pattern on EEG with interburst
    interval of 7sec. Repeat load as necessary to
    max of 15 mg/Kg, then maintain at 1-3 mg/Kg/hr
    x6-12 hours, then reevaluate

77
VUMC Status Epilepticus PathwaysPhase III 1-24
hrs (NCU) Goals
  • EEG is completed within 1 hour of call
  • Maintain hemodynamic stability
  • Treat hyperthermia
  • Identify etiology of seizures and develop
    appropriate plan of care
  • Patient returns to normal level of consciousness
    post seizures

78
VUMC Status Epilepticus PathwaysPhase III 1-24
hrs (NCU) Treatments
  • Neuro checks
  • Admission weight
  • Aspiration precautions
  • VS on admission and Q 4 hours
  • Rails up and safety checks Q 2 hours
  • Pad side rails

79
VUMC Status Epilepticus PathwaysPhase III 1-24
hrs (NCU) Labs
  • Bedside glucose at 2 hours for patient continuing
    to seize

80
VUMC Status Epilepticus PathwaysPhase III 1-24
hrs (NCU) Meds/IV
  • Maintenance AEDs as indicated, such as
  • Phenytoin 200-400 mg/day, or
  • Carbamazepine 200 mg bid, then increase by 200 mg
    Qod to 7-15 mg/Kg/day or
  • Phenobarbital 60-120 mg Qhs or
  • Divalproex 10-15 mg/Kg/day in 3 divided doses,
    then increase by 5-10 mg/Kg/day to 15-45 mg/Kg/day

81
VUMC Status Epilepticus PathwaysDay 2 (NCU
11S) Goals
  • Disposition plan developed
  • If ETOH/drug induced detox referral
  • If known epilepsy and seizures back to
    baseline/acceptable level, plan D/C for early am
    day 3
  • If meningitis/stroke/metabolic/other cause
    identified, transfer to appropriate path and
    manage accordingly

82
VUMC Status Epilepticus PathwaysDay 3 (11S
D/C) Goals
  • Patient to be D/Ced from VUMC when following
    criteria are met
  • awake
  • back to baseline LOC/functioning
  • Source of seizures is identified and appropriate
    disposition planned
  • Maintenance AEDs initiated (when indicated)
  • Patient agrees with plan

83
Case
  • A 65yr. Old female is acting confused for the
    last 1 week. The confusion fluctuates and its
    nadir she is unable to recognize any of her
    family members.
  • O/E she can not recall her address or DOB
  • She is afebrile and neck is supple
  • No history of epilepsy

84
Case
  • Labs
  • CBC, SMA 7 normal
  • Head CT normal
  • Spinal Tap normal
  • EEG continues ictal discharge were seen
  • Diagnosis Non Convulsive Status Epilepticus

85
Do not miss non-convulsive status
  • Non convulsive status epilepticus is a term used
    loosely to describe absence status, complex
    partial status and end stage convulsive S.E.
  • Do not give paralytics for patients with
    convulsive status epilepticus. This may abolish
    the outward expression of the seizures while the
    brain continues to have epileptic activity.

86
Ketogenic diet
  • Ketosis improves seizure control
  • The basic protocol calls for a diet with a
    fat-tocarbohydrate-plus-protein ratio of 4 to 1
    on a caloric basis. A modification of the diet
    uses medium-chain triglyceride (MCT) oil and
    allows for a greater amount of carbohydrate. The
    MCT oil diet is not clearly more beneficial, nor
    is it better tolerated.
  • beneficial in a subset of patients who have not
    responded to antiepileptic drugs. It is used
    predominantly in children.

87
Epilepsy surgery
  • Approximately 2030 of patients with epilepsy do
    not respond to anticonvulsant drugs
  • Selection Criteria
  • A precise diagnosis of seizure type and exclusion
    of patients with nonepileptic events.
  • Documented failure of seizure control on adequate
    blood concentrations of appropriate
    anticonvulsant drugs.
  • The seizure focus is defined in a part of the
    brain that can be resected with a low probability
    of causing a functional impairment that is worse
    than the intractable seizures.

88
Epilepsy surgery
  • Adequate time to establish that seizures are
    refractory to medical treatment. In adults, this
    is usually 6 months to 2 years, but in special
    circumstances, such as epilepsia partialis
    continua, less time is needed. In children,
    shorter waiting periods are indicated when
    seizures are causing developmental delay.

89
Epilepsy surgeryPresurgical evaluation.
  • EEG-CCTV
  • MRI
  • PET/ ictal SPECT
  • Neuropsycholgical testing
  • Wada test

90
Epilepsy surgery Surgical Procedures
  • Focal Cortical Resection
  • In general, an anterior temporal lobectomy is
    performed for mesial temporal lobe seizures, but
    variations include an anterior medial resection
    or, in some cases, an amygdalohippocampectomy.
    When a specific structural lesion is identified,
    such as a tumor or malformation, the goals of
    surgery are removal of the abnormality and
    resection of epileptogenic tissue with careful
    attention to sparing functional tissue.
  • Extratemporal cortical resections are less common
    because extratemporal epileptic foci are less
    common and more difficult to localize, and
    resection is more likely to cause a functional
    deficit.

91
Epilepsy surgery
  • Hemispherectomy Sturge-Weber syndrome, diffuse
    cortical dysplasias, hemimeganencephaly,
    unilateral congenital injuries, and Rasmussen's
    encephalitis. Because the involved cortex is
    already dysfunctional, hemispherectomy usually
    does not significantly increase motor, sensory,
    or cognitive impairment.
  • Corpus Callosotomy
  • Generalized seizures, especially atonic seizures,
    show the greatest benefit from callosal section.

92
Epilepsy
  • Epilepsy is a treatable condition and
    epileptic patients can live a normal and healthy
    life. Epilepsy should not be a social taboo

93
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com